Target intelligence / Profile preview

Emulsion Adjuvant Mechanism for Immune Stimulation

Molecular classification
Formulation/Physical Mechanism, Immunological Mechanism
01

Overview

This entry refers to a class of vaccine adjuvant mechanisms where forming an oil-in-water emulsion (often incorrectly described as water-in-oil in the query) enhances immune system activity. Such emulsions serve as vaccine adjuvants, increasing the recruitment and activation of antigen-presenting cells, facilitating antigen uptake, and promoting cytokine/chemokine production in local tissues to stimulate a more robust adaptive immune response. Well-characterized examples include MF59 and AS03, used in influenza and COVID-19 vaccines. These formulations are not individual molecular targets but are categorized by formulation and immunological function. Safety and efficacy depend on both immunological effects and physical emulsion stability.

Other names
Emulsion adjuvant mechanismOil-in-water emulsion adjuvant mechanismAntigen presentation enhancement via emulsion adjuvant
02

Mechanism of action

Slow/controlled release and depot effect for antigen; Recruitment and activation of immune cells (monocytes, dendritic cells, neutrophils) to injection site and draining lymph nodes; Enhanced uptake and presentation of antigen by APCs (e.g., dendritic cell maturation, increased co-stimulatory molecule expression); Modulation of local chemokine/cytokine production to promote adaptive immune response.

03

Biological functions

Immune response (adjuvantation)Enhanced antigen presentationRecruitment and activation of antigen-presenting cells (APCs), especially dendritic cells and monocytes
04

Disease associations

Infection (vaccine development against viral and bacterial infections)Other (potential applicability to cancer vaccines)
05

Safety considerations

Local reactogenicity at the injection site (inflammation, soreness)Rare risk of systemic inflammatory or autoimmune reactionsPast adjuvants (e.g., in Pandemrix/AS03 for H1N1 flu) have been controversially linked to increased narcolepsy risk in some populations, although causality is debatedStability and consistent emulsion formation are critical; instability may impact safety and efficacy
06

Interacting drugs

MF59

3 more in the full profile.

07

Biomarkers

Enhanced expression of dendritic cell activation markers (CD80, CD86, HLA-DR, CD54, CD83)Cytokine secretion (IL-6, IL-8, others variably)

Beyond the preview

Go deeper on Emulsion Adjuvant Mechanism for Immune Stimulation.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emulsion Adjuvant Mechanism for Immune Stimulation.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call